203 related articles for article (PubMed ID: 8535309)
1. Short-term in vivo priming of bone marrow haematopoiesis with rhG-CSF, rhGM-CSF or rhIL-3 before marrow harvest expands myelopoiesis but does not improve engraftment capability.
Hansen PB; Knudsen H; Gaarsdal E; Jensen L; Ralfkiaer E; Johnsen HE
Bone Marrow Transplant; 1995 Sep; 16(3):373-9. PubMed ID: 8535309
[TBL] [Abstract][Full Text] [Related]
2. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
3. [Shore-term stimulation with myeloid growth factors expands bone marrow hematopoiesis. A magnetic resonance spectroscopic study].
Hansen B; Jensen KE; Larsen VA; Johnsen HE; Nielsen H; Karle H; Henriksen O
Ugeskr Laeger; 1995 Nov; 157(45):6265-9. PubMed ID: 7491720
[TBL] [Abstract][Full Text] [Related]
4. Increased yield of myeloid progenitor cells in bone marrow harvested for autologous transplantation by pretreatment with recombinant human granulocyte-colony stimulating factor.
Johnsen HE; Hansen PB; Plesner T; Jensen L; Gaarsdal E; Andersen H; Hansen SW; Birgens H; Jacobsen GK; Kjaersgaard E
Bone Marrow Transplant; 1992 Sep; 10(3):229-34. PubMed ID: 1384899
[TBL] [Abstract][Full Text] [Related]
5. Priming with recombinant human hematopoietic cytokines before bone marrow harvest expands in vivo and enhances ex vivo recovery of myeloid progenitors in short-term liquid cultures.
Johnsen HE; Jensen L; Gaarsdal E; Hansen PB; Ersbøll J; Hansen NE
Exp Hematol; 1994 Jan; 22(1):80-6. PubMed ID: 7506675
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma.
Fay JW; Bernstein SH
Semin Oncol; 1996 Apr; 23(2 Suppl 4):22-7. PubMed ID: 8600545
[TBL] [Abstract][Full Text] [Related]
7. Antagonistic effects of interleukin 6 and G-CSF in the later stage of human granulopoiesis in vitro.
Katayama K; Koizumi S; Ueno Y; Ohno I; Ichihara T; Horita S; Miyawaki T; Taniguchi N
Exp Hematol; 1990 Jun; 18(5):390-4. PubMed ID: 1692536
[TBL] [Abstract][Full Text] [Related]
8. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
[TBL] [Abstract][Full Text] [Related]
9. Granulocyte-macrophage colony-stimulating factor accelerates hematopoietic recovery after autologous bone marrow or peripheral blood progenitor cell transplantation and high-dose chemotherapy for lymphoma.
Colombat P; Delain M; Desbois I; Domenech J; Binet C; Tabah I; Lamagnere JP; Linassier C
Bone Marrow Transplant; 1996 Aug; 18(2):293-9. PubMed ID: 8864437
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
[TBL] [Abstract][Full Text] [Related]
11. Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation.
Ippoliti C; Przepiorka D; Giralt S; Andersson BS; Wallerstein RO; Gutterman J; Deisseroth AB; Champlin RE
Bone Marrow Transplant; 1993 Jan; 11(1):55-9. PubMed ID: 8094309
[TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
[TBL] [Abstract][Full Text] [Related]
14. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study.
Fay JW; Lazarus H; Herzig R; Saez R; Stevens DA; Collins RH; Piñeiro LA; Cooper BW; DiCesare J; Campion M
Blood; 1994 Oct; 84(7):2151-7. PubMed ID: 7919329
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) administration after autologous bone marrow transplantation for acute myeloblastic leukemia enhances activated killer cell function and may diminish leukemic relapse.
Richard C; Baro J; Bello-Fernandez C; Hermida G; Calavia J; Olalla I; Alsar MJ; Loyola I; Cuadrado MA; Iriondo A
Bone Marrow Transplant; 1995 May; 15(5):721-6. PubMed ID: 7670401
[TBL] [Abstract][Full Text] [Related]
16. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
17. Different response to recombinant human granulocyte-macrophage colony-stimulating factor in primary and secondary graft failure after bone marrow transplantation.
Sierra J; Terol MJ; Urbano-Ispizua A; Rovira M; Marin P; Carreras E; Batlle M; Rozman C
Exp Hematol; 1994 Jul; 22(7):566-72. PubMed ID: 8013572
[TBL] [Abstract][Full Text] [Related]
18. Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF.
Rosenfeld CS; Bolwell B; LeFever A; Taylor R; List A; Fay J; Collins R; Andrews F; Pallansch P; Schuster MW; Resta D; Levitt D; Nemunaitis J
Bone Marrow Transplant; 1996 Feb; 17(2):179-83. PubMed ID: 8640163
[TBL] [Abstract][Full Text] [Related]
19. Sequential administration of interleukin-6 and granulocyte-colony stimulating factor in newborn rats: modulation of newborn granulopoiesis and thrombopoiesis.
Cairo MS; Plunkett JM; Nguyen A; Clark S; van de Ven C
Pediatr Res; 1991 Dec; 30(6):554-9. PubMed ID: 1725208
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
Sosman JA; Stiff PJ; Bayer RA; Peliska J; Peace DJ; Loutfi S; Stock W; Oldenburg D; Unverzagt K; Bender J
Bone Marrow Transplant; 1995 Nov; 16(5):655-61. PubMed ID: 8547862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
